Journal of the Neurological Sciences
Volume 222, Issue 1 , Pages 13-19 , 15 July 2004

High-dose, frequently administered interferon beta therapy for relapsing–remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study

Received 23 July 2003 ,Revised 19 March 2004 ,Accepted 20 March 2004.

References 

  1. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 1996;39:285–294
  2. The IFNβ Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–661
  3. The PRISMS study Group . Randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing–remitting multiple sclerosis. Lancet. 1998;352:1498–1504
  4. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452
  5. The IFNβ Multiple Sclerosis Study Group University of British Columbia MS/MRI Analysis Group . Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45:177–185
  6. Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, et al.  The effect of interferon-β on blood–brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing remitting multiple sclerosis. Ann. Neurol. 1995;37:611–619
  7. Stone LA, Frank JA, Albert PS, Bash C, Calabresi PA, Maloni H, et al.  Characterization of MRI response to treatment with interferon beta-1b: contrast enhancing MRI lesion frequency as primary outcome measures. Neurology. 1997;49:862–869
  8. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, et al.  Guidelines for use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann. Neurol. 1996;39:6–16
  9. Miller A, Lanir N, Shapiro S, Revel M, Honigman S, Kinarty A, et al.  Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis and other autoimmune diseases. J. Neuroimmunol. 1996;64:151–161
  10. Rudick RA, Simonian MA, Alam JA, Campion M, Scaramucci JO, Jones W, et al.  Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology. 1998;50:1266–1272
  11. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Grezzi A, et al.  Every-other-day interferon beta-1b versus once-a-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet. 2001;359:1453–1460
  12. Panitch H, et al.  for the EVIDENCE (EVidence of Interferon Dose–response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research group   Randomized, comparative study of interferon beta-1a treatment regimens in MS. The EVIDENCE Trial. Neurology. 2002;59:1496–1506
  13. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983;13:227–231
  14. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Battistelli S, Correnti M, et al.  Development of neutralizing antibodies in patients with relapsing remitting multiple sclerosis treated with IFN beta-1a. J. Interferon Cytokine Res. 1998;18:345–350
  15. Goodkin DE, Ross JS, Medendorp SV, Konecsni J, Rudick RA. Magnetic resonance imaging lesion enlargement in multiple sclerosis. Disease-related activity, chance occurrence or measurement artifact?. Arch. Neurol. 1992;49:261–263
  16. Filippi M, Gawne-Cain ML, Gasperini C, vanWaesberghe JH, Grimaud J, Barkhof F, et al.  Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology. 1998;50:238–244
  17. Filippi M, Rovaris M, Campi A, Pereira C, Comi G. Semiautomated thresholding technique for measuring lesion volumes in multiple sclerosis: effects of the change of the threshold on the computed lesion loads. Acta Neurol. Scand. 1996;93:30–34
  18. Khan OA, Hebel JR. Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing–remitting multiple sclerosis. Ann. Neurol. 1998;44:138–139
  19. Evidence of interferonβ-1a dose response in relapsing–remitting MS. The OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology. 1999;53:679–686
  20. Rice GPA, Incorvaia AB, Munari L. Interferon in relapsing–remitting multiple sclerosis (Cochrane review). In: The Cochrane Library, Issue 4. Oxford: Update Software; 2001;p. 853–863
  21. Stuve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, et al.  Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 1996;40:853–863
  22. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T-cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 1996;40:846–852
  23. Alam J, Goelez S, Rioux P, Scaramucci J, Jones W, McAllister A, et al.  Comparative pharmacodynamics of two recombinant human interferon beta-1a (IFNβ-1a) products administered intramuscularly in healthy male and female volunteers. Pharm. Res. 1997;14:546–549
  24. Sturzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrinke B. Pharmacodynamic comparison of single doses of IFNβ-1a and IFNβ-1b in healthy volunteers. J. Interferon Cytokine Res. 1999;19:1257–1264
  25. Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M. A phase I study of recombinant interferon beta in patients with advanced malignant disease. Clin. Cancer Res. 1999;5:3990–3998
  26. Takano S, Satomura Y, Omata M. Effects on interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Gastroenterology. 1994;107:805–811
  27. Kermode AG, Tofts PS, Thompson AJ, MacManus DG, Rudge P, Kendall BE, et al.  Heterogeneity of blood–brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology. 1990;40:229–235
  28. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, et al.  Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann. Neurol. 1992;32:758–766
  29. Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, et al.  Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and change in disability or impairment in multiple sclerosis: a meta-analysis. Lancet. 1999;353:964–969
  30. Li DK, Zhao G, Paty DW. T2 hyperintensities: findings and significance. Neuroimaging Clin. N. Am. 2000;10:717–738

PII: S0022-510X(04)00091-7

doi: 10.1016/j.jns.2004.03.023

Journal of the Neurological Sciences
Volume 222, Issue 1 , Pages 13-19 , 15 July 2004

Article Tools

* Image Usage & Resolution